Today's Date: June 30, 2022
Five Bluum Standouts Honored on CRN 2022 Women of the Channel List   •   RNR Tire Express Surprises Tampa-Area Woman with New Car in Mother's Day Giveaway   •   Checkmarx' Ana Lucia Amaral Honored as a CRN 2022 Woman of the Channel   •   Citizens for Judicial Fairness and Reverend Al Sharpton Applaud Nomination of Justice Tamika Montgomery-Reeves to Third Circuit   •   Global Surrogacy Services Announces Outreach to Potential Gestational Surrogates in Three Southwestern States   •   Xfinity Stream app Launches on Apple TV 4K and Apple TV HD   •   Equitable Bank Releases Inaugural ESG Performance Report   •   Closing the Health Disparity Gap for Black Women   •   Silver Spring Foods Releases First-Ever Non-GMO Horseradish Just in Time for National Horseradish Month   •   VNA Health Care Discusses the Importance of Mammography and Cervical Cancer Screenings   •   Southern Glazer’s Wine & Spirits Donates $25,000 to Ali Forney Center in Honor of Pride Month   •   Tracey Hayes from MicroAge Named on CRN's 2022 Women of the Channel Power 70 Solution Providers List   •   NCCI Golf Event Generates $25,000 for Kids' Chance of America Scholarships   •   Four recipients of the 2022 Awards of Excellence in Nursing announced from Indigenous Services Canada   •   Tractor Supply Company Celebrates Service Members With Nationwide Discount on the Fourth of July and Announces Grant Donation fo   •   Mrs. Flowers Takes the Helm at Comfort Home Care, Rockville, MD   •   Mia Becar to Launch Equity Crowdfunding Campaign   •   Cinemark Brings the Ultimate Cinematic Experience to Riverton with Mountain View Village Theatre Now Open   •   Eight Ameriprise Financial Advisors Named to the Barron’s Top 100 Women Financial Advisors List   •   Prime Capital Investment Advisors Partners With Female-led Crossvault Capital Management
Bookmark and Share

Celmatix Announces Achievement of Key Preclinical Milestones in Premature Menopause Prevention Drug Program

NEW YORK , May 16 /Businesswire/ - Celmatix Inc. a biotechnology company focused on ovarian biology, today announced the identification of a novel AMHR2 agonist compound that has demonstrated robust biological activity in multiple therapeutically relevant preclinical assays and a pharmacokinetic profile consistent with the desired product profile for an injectable drug. The program, which was a product of Celmatix’s decade-long focus on identifying novel biomarkers and drug targets for women’s health, has a planned first clinical indication in the prevention of premature menopause in women undergoing chemotherapy. Loss of ovarian function and menopause are accelerated by approximately 1.5 years for each month a woman receives chemotherapy treatment.

“Demographically speaking, menopause is a relatively new phenomenon and is the result of medical breakthroughs that allow women to now routinely outlive their ovarian function” remarked Dr. Piraye Yurttas Beim, Celmatix founder and CEO. “A century ago, the average life expectancy for women globally was under 50, so most women did not live long enough to experience menopause. Today, it is the single most significant accelerator of age-related conditions such as osteoporosis and heart disease in women. The risk for developing multiple of these chronic diseases by age 70 increases by 300% for women who experience premature loss of ovarian function and menopause. At Celmatix we are committed to helping women maximize their health by optimizing and extending ovarian function. Our team has worked for over a decade to uncover the molecular drivers of ovarian health and related conditions like infertility, polycystic ovary syndrome (PCOS), and endometriosis. Through this work, it became clear to us that Anti-Müllerian Hormone (AMH), the natural ligand of AMHR2, is a fundamental regulator of ovarian function, much like estrogen. Unlike estrogen, however, AMH cannot be purified from natural sources like urine or chemically synthesized, and previous attempts failed to generate recombinant AMH analogs with high specific activity or pharmacokinetic stability necessary for therapeutic applications.”

"One of the things that attracted me as a drug developer to Celmatix was the potential of the AMHR2 agonist program to address significant unmet needs in women's health” explained Dr. Stephen Palmer, Chief Scientific Officer of Celmatix. "It was clear to me that Celmatix’s AMHR2 agonist program is on track to be a 21st century breakthrough, equivalent to the development last century of the birth control pill and IVF drugs. Our lead indication is chemotherapy induced ovarian failure (CIOF), but we believe that an AMHR2 agonist may also have applications in a broad range of women’s health indications. Our results demonstrate that our lead AMH analog has the desired in vivo pharmacokinetic parameters and causes the desired cellular signaling events in traditional ovarian follicular assays and regression of the Müllerian ducts in ex vivo urogenital ridge culture systems. Demonstrating high specific activity in both our target tissue (the ovary) and in the most well-established assay for AMH function gives us confidence to progress this program forward closer to the clinic.”

This announcement closely follows Celmatix’s achievement of the third milestone in its five-year, multi-target alliance with Evotec in January. The milestone was triggered by Evotec and Bayer AG advancing a drug program, centered around a novel Celmatix-identified drug target, into hit-identification.

About Celmatix

Celmatix Inc. is a preclinical-stage women’s health biotech focused uniquely on ovarian biology. With a lead “pipeline-in-a-pill” AMHR2 agonist program focused on ovarian senescence, and collaborations in PCOS and non-hormonal contraception with industry leaders, Celmatix is addressing areas of high unmet need by developing the next generation of interventions and pioneering advancements in ovarian health. Celmatix’s proprietary multi-omic ovarian health platform, the world’s largest of its kind, is the foundation of the company’s novel pipeline of first-in-class therapies. For more information, visit the company’s website at www.celmatix.com


STORY TAGS: New York, United States, North America, Canada, Science, Women, Biotechnology, Research, Pharmaceutical, Health, Consumer, Clinical Trials, Product/Service,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News